What Type of Cancer Causes High Iron Levels?

Several types of cancer are associated with high iron levels, but the relationship runs in both directions: some cancers thrive because of excess iron, while others actively drive iron levels up as part of the disease process. Hepatocellular carcinoma (liver cancer) has the strongest and longest-studied link to iron overload, but renal cell carcinoma, certain lymphomas, myelodysplastic syndromes, and several other malignancies also raise serum ferritin, the blood marker most commonly used to gauge iron stores. The picture is more complicated than a single diagnosis, and understanding why iron climbs in cancer turns out to be just as important as knowing which cancers are involved.

Liver Cancer Has the Strongest Link to Iron Overload

Hepatocellular carcinoma was the first cancer convincingly tied to chronic iron excess. The connection was initially discovered in people with hereditary hemochromatosis, a genetic condition that causes the body to absorb too much iron from food. A large study of hemochromatosis patients found they carried roughly a 20-fold increased risk of liver cancer compared to the general population, while their risk of all other cancers was barely elevated at all.¹ That striking specificity pointed to something about iron accumulation in the liver itself, rather than a body-wide cancer-promoting effect.

The mechanism makes intuitive sense. When iron builds up in liver tissue, it generates reactive oxygen species through a chemical process that damages DNA and other cellular structures. Over time, that sustained damage promotes scarring (fibrosis and eventually cirrhosis), and cirrhotic tissue is fertile ground for cancerous transformation.² Elevated serum ferritin in this setting reflects a genuinely high iron load in the liver, and rising ferritin over time may signal worsening liver disease and increasing cancer risk.³

This is worth pausing on, because liver cancer illustrates the “chicken or egg” problem with iron and cancer more clearly than almost any other malignancy. The iron comes first, sits in the liver for years or decades, and eventually contributes to a tumor forming. In many other cancers, the sequence is reversed.

Renal Cell Carcinoma Pumps Out Ferritin

Kidney cancer, specifically renal cell carcinoma, is one of the clearest examples of a tumor that actively produces and releases ferritin into the bloodstream. In one study, ferritin levels in kidney cancer patients averaged about 259 ng/mL compared to roughly 61 ng/mL in controls, and those levels climbed steadily with more advanced disease. After surgical removal of the tumor in early-stage patients, ferritin levels dropped significantly.⁴

Researchers confirmed where the ferritin was coming from by measuring it directly in blood draining from the tumor. In one patient with a large tumor, ferritin sampled from the renal vein was dramatically higher than in blood drawn from elsewhere, strongly suggesting the tumor itself was the source. Tissue from the tumors stained intensely positive for both iron and ferritin, while adjacent healthy kidney tissue did not.⁵ This makes renal cell carcinoma somewhat unusual: the tumor is not just hoarding iron for its own use but actively flooding the bloodstream with ferritin, which is why the protein has been explored as a tumor marker for kidney cancer specifically.

Blood Cancers and Disordered Iron Handling

Several blood cancers are associated with elevated iron, though the reasons differ depending on the specific disease.

Myelodysplastic syndromes, a group of bone marrow disorders that can progress to acute leukemia, commonly show high ferritin even before patients receive any blood transfusions. The bone marrow in these conditions makes red blood cells inefficiently, which paradoxically signals the gut to absorb more iron from food than the body needs.⁶ Once patients start receiving regular transfusions to manage their anemia, iron levels can climb much further, because the body has no efficient way to get rid of excess iron from transfused blood.⁷

Lymphomas produce a different pattern. When certain lymphomas trigger a dangerous inflammatory condition called hemophagocytic lymphohistiocytosis (HLH), ferritin can skyrocket to levels far beyond what most other diseases produce. A review of lymphoma-associated HLH found a median ferritin of about 4,800 µg/L, with nearly a third of patients exceeding 15,000 µg/L. T-cell lymphomas tended to push ferritin even higher than B-cell lymphomas, with median levels roughly two to three times as high.⁸ These extreme ferritin levels are driven less by actual iron stores than by massive inflammation and cell destruction, which makes the ferritin number more of a danger signal about the intensity of the immune response than a reflection of how much iron is sitting in the body.

Other Cancers Where Ferritin Climbs

The list extends beyond the liver, kidneys, and blood. In breast cancer, research has found that a substantial portion of patients have elevated ferritin, with the proportion climbing among those with locally advanced or metastatic disease.⁹ In gynecological cancers, patients with high ferritin at diagnosis had significantly shorter survival compared to those with normal or low levels.¹⁰ In advanced colorectal cancer, elevated ferritin independently predicted poorer survival even after accounting for other known prognostic markers.¹¹

The common thread across these cancers is that ferritin tends to rise with more advanced disease and correlates with worse outcomes. But the reasons it rises are not identical in every case. Some tumors secrete ferritin directly. Some trigger systemic inflammation that drives ferritin up as a byproduct. And some do both. This is important context for anyone staring at an unexpectedly high ferritin number on a lab report.

Why Tumors Need So Much Iron

Cancer cells divide rapidly, and cell division is iron-hungry work. Iron is essential for DNA synthesis, energy production in mitochondria, and several enzymes that rapidly growing cells depend on. Tumor cells have evolved multiple ways to ensure they get enough iron to sustain their growth. They can manipulate hepcidin, the hormone that controls how much iron enters the bloodstream, so that the normal regulatory system works in the tumor’s favor rather than the body’s.¹²

A striking recent discovery showed that tumors that spread to bone actually hijack a specialized type of immune cell (macrophage) whose normal job is to deliver iron to developing red blood cells. The tumor redirects those iron-carrying macrophages to feed itself instead, which starves the red blood cell precursors of iron and contributes to the anemia that many cancer patients experience.¹³ This finding neatly explains something clinicians have long observed: cancer patients often have both high ferritin (suggesting plenty of iron in the body) and anemia (suggesting not enough iron is reaching red blood cells). The iron is there; it’s just being diverted.

There is also a dark irony to the tumor’s iron addiction. The same excess iron that feeds cancer growth also puts cells at risk of a form of cell death called ferroptosis, which is triggered by iron-dependent damage to cell membranes. Cancer cells have to walk a tightrope, accumulating enough iron to grow while building defenses against the ferroptotic death that excess iron can trigger.¹⁴ This vulnerability is now one of the most active areas in cancer research.

High Ferritin Does Not Necessarily Mean Cancer

Before anyone panics over a high ferritin lab result, it helps to know that only about 10% of cases of elevated ferritin are caused by genuine iron overload of any kind. The rest are driven by inflammation, infection, liver disease, autoimmune conditions, and other non-iron-related reasons.¹⁵ Ferritin is what doctors call an acute-phase reactant, meaning the body pumps out more of it in response to almost any significant stress, illness, or inflammation. A bad flu, a flare of rheumatoid arthritis, or a fatty liver can all push ferritin well above the normal range.

This is exactly why ferritin alone cannot diagnose cancer. A doctor who sees elevated ferritin will typically check additional labs to figure out whether the iron stores themselves are truly high (which points toward hemochromatosis or true iron overload) or whether the ferritin is rising as part of an inflammatory response (which opens up a much wider list of possible causes). Transferrin saturation, C-reactive protein, and liver function tests are usually part of that workup. If iron overload is confirmed and there is no obvious explanation like hereditary hemochromatosis or repeated transfusions, imaging of the liver and further investigation may follow.

When High Iron Predicts a Worse Outcome

For patients who already have a cancer diagnosis, the ferritin level can carry prognostic information. In metastatic colorectal cancer, elevated ferritin was an independent predictor of shorter survival, meaning it added prognostic value even beyond standard markers.¹¹ The same pattern has appeared in gynecological cancers, where higher ferritin at diagnosis correlated with significantly shorter survival.¹⁰ And in lymphoma-associated HLH, the extreme ferritin elevations signal an especially aggressive disease course.⁸

The likely explanation is that very high ferritin reflects a combination of aggressive tumor biology, heavy tumor burden, and intense systemic inflammation, all of which independently worsen prognosis. Ferritin itself probably is not causing the bad outcomes; it is more of a thermometer reading that tells you how hot the fire is. Still, because it is cheap and easy to measure, there is growing interest in using it as part of a panel of prognostic markers rather than relying on more expensive or invasive tests alone.

Transfusion-Related Iron Overload in Cancer Patients

Some cancer patients develop high iron levels not because of the tumor itself but because of the treatment. Patients with blood cancers or bone marrow failure often need repeated red blood cell transfusions, and each unit of blood delivers a significant dose of iron that the body cannot easily excrete. In a study of children with blood cancers and bone marrow failure syndromes, roughly two-thirds already had elevated ferritin at the start of treatment, and that proportion grew over six months of follow-up as transfusions accumulated. More than half ended the observation period with ferritin above 1,000 ng/mL, and the final ferritin level tracked closely with how many transfusions they had received.¹⁶

This form of iron overload is medically significant because the excess iron deposits in the heart, liver, and endocrine organs, potentially causing organ damage that complicates an already difficult clinical picture. It is one of the reasons that iron chelation therapy, which uses drugs to bind and remove excess iron from the body, is part of the treatment plan for many chronically transfused patients.

Iron Chelation as a Cancer Treatment Strategy

The idea of starving tumors of iron has been tested in the lab and, to a limited degree, in clinical settings. Early work showed that the iron chelator deferoxamine could markedly slow the growth of aggressive tumors like neuroblastoma and leukemia in preclinical models, which prompted the development of newer chelating agents for possible cancer use.¹⁷

More recently, researchers found that deferiprone, an iron chelator already approved for use in patients with thalassemia, reprogrammed ovarian cancer cells in a way that made them visible and vulnerable to the immune system. In mouse models, deferiprone combined with chemotherapy significantly extended survival by activating immune cells that attacked metastatic disease.¹⁸ This is still preclinical work, and iron chelation is not a standard cancer therapy in humans, but it represents a creative approach: rather than targeting the tumor directly, you target the resource it depends on.

The ferroptosis angle adds another dimension. Because cancer cells must accumulate iron while defending against iron-triggered cell death, drugs that disrupt those defenses could theoretically push cancer cells over the edge into ferroptosis. Several research groups are working on ways to exploit this vulnerability, and the tumor microenvironment’s influence on how both cancer cells and immune cells handle iron-related stress is an area of active investigation.¹⁹ Whether these approaches will translate into effective treatments for people remains to be seen, but the biology is promising enough that multiple clinical trials are underway or in planning stages.

How Bone Metastases Contribute to Iron Imbalance

One of the more recent and surprising findings in this area involves cancers that spread to bone. Bone marrow is where red blood cells are made, and the process depends on specialized macrophages that deliver iron to developing red blood cells. When tumors metastasize to bone, they recruit these iron-ferrying macrophages and redirect the iron supply to feed tumor growth. The result is a double problem: the tumor gets the iron it needs to expand, and the red blood cell precursors are left iron-starved, contributing to the anemia seen in many patients with bone metastases.¹³

This mechanism helps explain a clinical puzzle that has frustrated doctors for years. A patient with widespread cancer may show ample iron stores on blood tests yet still be severely anemic. Traditional thinking attributed this to “anemia of chronic disease,” a somewhat vague category. The macrophage-hijacking discovery provides a much more specific explanation, at least for patients with bone involvement: the iron is being physically rerouted away from blood cell production. It also raises the possibility that blocking this hijacking, perhaps through targeted drugs or iron chelation, could address both the tumor’s iron supply and the patient’s anemia simultaneously. That dual-target approach is still theoretical, but it illustrates how rapidly the understanding of iron’s role in cancer is evolving.

1
PubMed. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives
2
PubMed Central. Hepatic iron overload and hepatocellular carcinoma
3
PubMed Central. Association between Serum Ferritin, Incident Primary Liver Cancer, and Chronic Liver Disease Mortality in the Linxian Nutrition Intervention Trials
4
PubMed. Serum ferritin: a tumor marker for renal cell carcinoma
5
Urology. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume
6
PubMed. Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome
7
PubMed Central. Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria
8
Leukemia. Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis
9
PubMed Central. Serum Ferritin, Vitamin D and Pathological Factors in Breast Cancer Patients
10
PubMed Central. Can serum ferritin serve as a biomarker for the prognosis of gynecological malignant tumors?
11
PubMed Central. Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer
12
PubMed Central. Distinctive modulation of hepcidin in cancer and its therapeutic relevance
13
Cell. Tumors hijack macrophages for iron supply to promote bone metastasis and anemia
14
PubMed Central. Ferroptosis and cancer: when iron turns against tumors
15
PubMed Central. Hyperferritinemia-A Clinical Overview
16
PubMed Central. Study of transfusion-related iron overload (trio) in pediatric patients with hematological malignancy and bone marrow failure syndromes
17
PubMed. Therapeutic potential of iron chelators in cancer therapy
18
Cancer Discovery. Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
19
PubMed Central. Immunometabolism of ferroptosis in the tumor microenvironment